Short Summary
Bayer Corporation appealed an order allowing Nacto Pharma Ltd. (NPL), a compulsory licensee, to export its product 'Sorafenat' outside India for clinical trials. Bayer alleged this violated the terms of the compulsory license granted under Section 84 of the Patents Act, 1970. The court directed that instead of deciding the appeal on merits, the underlying writ petition be disposed of expeditiously by impleading relevant regulatory authorities.
Detailed Summary
For founders and IP professionals, few legal battles illustrate the tension between patent rights and public access to medicine as sharply as a compulsory license dispute. When a government grants a third party the right to produce a patented drug without the inventor's consent, the boundaries of that permission become a high-stakes question. Bayer Corporation's clash with Nacto Pharma Ltd. over the export of a cancer drug called 'Sorafenat' is a textbook example of how a single clause in a compulsory license can trigger a courtroom war.
Bayer Corporation, a global pharmaceutical company, held patent rights over a drug marketed as Sorafenat. Under Section 84 of the Patents Act, 1970, the Controller of Patents had earlier granted a compulsory license to Nacto Pharma Ltd. (NPL), allowing it to manufacture the drug in India under specific conditions. The dispute arose when NPL sought—and obtained—an order permitting it to export Sorafenat outside India for the purpose of conducting clinical trials. Bayer, alarmed that its patented product was being shipped abroad by a licensee it never voluntarily authorized, challenged this move. Bayer contended that exporting the drug fell outside the scope of the compulsory license originally granted, and that the permission to export violated the terms and conditions attached to that license.
Bayer's central argument was straightforward: a compulsory license under Section 84 comes with defined boundaries, and exporting the drug for clinical trials abroad was not part of the deal. From Bayer's perspective, allowing NPL to ship Sorafenat overseas effectively extended the compulsory license beyond what was legally permissible, undermining Bayer's exclusive patent rights in foreign markets. Nacto Pharma, on the other hand, stood by the order permitting export, presumably arguing that clinical trial exports were a legitimate and necessary step in bringing the drug to broader markets. The legal friction centered on a single but powerful question: does a compulsory license granted for manufacture and sale in India automatically authorize export activities, or must such export rights be explicitly granted under Section 107-A of the Patents Act?
Rather than delivering a final ruling on the merits of Bayer's appeal, the court took a procedural but pragmatic approach. It directed that the underlying writ petition be disposed of expeditiously, with instructions to implead the relevant regulatory authorities who had a stake in the export decision. By remanding the matter, the court acknowledged that the question of whether NPL could export Sorafenat under its compulsory license required the participation of regulators who could speak to the conditions imposed by the licensing authority. The court implicitly recognized that the scope and limitations of the compulsory license—particularly the export angle under Section 107-A—had to be examined in light of the specific terms originally attached to the license.
For founders, startup leaders, and IP professionals, this case delivers a clear and practical lesson: the scope of a compulsory license is not a blank check. If your business relies on—or competes with—a compulsory licensee, you must scrutinize the exact conditions imposed by the licensing authority, especially when export rights under Section 107-A come into play. Conversely, if you are operating under a compulsory license, do not assume that domestic manufacturing rights translate into international freedom of movement. Always map the boundaries of your license before shipping product across borders, and engage the relevant regulatory authorities early to avoid costly courtroom detours.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Bayer Corporation vs Union Of India And Others is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
The North Face Apparel CorpvsController of Patents and Designs
The North Face Apparel Corp challenged the Controller of Patents' refusal of its patent application (No. 202147026139) titled 'Systems and Methods for End-to-End Article Management' before the Madras High Court under Section 117A of the Patents Act, 1970. The Controller had rejected the application citing lack of inventive step over prior art documents D21-D24. The Court held that the Controller erred by dissecting the claims into isolated elements rather than assessing the invention as a whole, and overlooked the use of spectrophotometer and invisible markers for tracking the manufacturing process, which were not disclosed in the cited prior art. The appeal was allowed and the Controller was directed to grant the patent.
Aventose Energy Private LimitedvsThe Assistant Controller of Patents & Designs, Patent Office Chennai
Aventose Energy Private Limited appealed under Section 117A of the Patents Act, 1970 against the refusal of its patent application (No. 202141019671) for a 'System and Method for Operating Automobiles with an Electric Drivetrain' featuring safe mode activation upon fault detection. The Madras High Court found that the Assistant Controller had contradicted the First Examination Report (which accepted novelty) by subsequently holding the invention lacked novelty without giving the applicant an opportunity to be heard. The court further held that the Controller improperly conflated novelty with inventive step under Section 2(1)(ja) and failed to properly analyze the claims against prior art documents D1–D4.
Apex Laboratories Pvt LtdvsElder Lifescience and Ambico Ayurvedic Health Care
Apex Laboratories Pvt Ltd, the prior adopter and registered proprietor of the trademark ZINCOVIT (TM No. 487453 in Class 5) since 1988, sought interim injunction against Elder Lifescience and Ambico Ayurvedic Health Care for using the deceptively similar mark NEO ZINCOVIT. The applicant also claimed copyright infringement of its registered artistic works (A-108878/2014) covering colour scheme, get-up, and layout. The Madras High Court was satisfied that the respondents were attempting to piggyback on the applicant's goodwill and granted interim injunctions on all three applications covering trademark infringement, copyright infringement, and passing off.
Radico Khaitan LimitedvsPicadilly Agro Industries Limited
This Special Leave Petition arose from a judgment dated 29-05-2026 in CS No. 8/2025 passed by the District Judge, Karnal, Haryana, concerning a trademark dispute over the marks 'Cashmere' and 'Kashmyr' used in relation to beer and vodka. The Supreme Court noted that a First Appeal (FAO-COM-11-2026) was already pending before the Division Bench of the Punjab and Haryana High Court, listed for 28.10.2026. The Court disposed of the SLP without adjudicating it on merits, requesting the High Court to pass an appropriate order regarding the ad interim injunction on the scheduled date.
Maharaja Agrasen Technical Educational Society (Regd.)vsMaharaja Agrasen Himalayan Garhwal University
The plaintiff, Maharaja Agrasen Technical Educational Society, filed a suit for permanent injunction against the defendant, Maharaja Agrasen Himalayan Garhwal University, alleging infringement and passing off regarding the use of the words 'Maharaja Agrasen' in the defendant's name. The Delhi High Court had previously granted a restraint order on 10.07.2026. During the pendency of the suit, the parties arrived at a settlement dated 14.09.2026, under which the defendant agreed to change its name through a statutory amendment while being permitted limited transitional use of its existing name. The court recorded the settlement, modified the interim order accordingly, and listed the matter for compliance reporting on 13.07.2027.
Varahi Diamonds And Finance LimitedvsSahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr.
This is a commercial suit filed by Varahi Diamonds And Finance Limited against Sahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr. before the Delhi High Court. The order is primarily procedural, dealing with the registration of the plaint, issuance of summons, directions for filing pleadings, and an interim injunction application. The matter was referred to mediation, with parties directed to appear before the Delhi High Court Mediation and Conciliation Centre.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.